deltatrials
Unknown PHASE4 NCT05269615

Exercise-induced Erythropoiesis: the Mechanistic of Angiotensin II

Sponsor: The University of Hong Kong

Conditions Exercise Physiology
Interventions Placebo Valsartan 80 mg
Updated 9 times since 2022 Last updated: May 8, 2024 Started: Mar 20, 2023 Primary completion: Sep 30, 2024 Completion: Sep 30, 2024

A PHASE4 clinical study on Exercise Physiology, this trial is ongoing. The trial is conducted by The University of Hong Kong and has accumulated 9 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

9 versions recorded

  1. Jan 2026 — Present [monthly]

    Unknown PHASE4

    Status: Recruiting → Unknown

  2. Sep 2024 — Jan 2026 [monthly]

    Recruiting PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE4

  4. Jun 2024 — Jul 2024 [monthly]

    Recruiting PHASE4

  5. Dec 2023 — Jun 2024 [monthly]

    Recruiting PHASE4

▶ Show 4 earlier versions

  1. Jun 2023 — Dec 2023 [monthly]

    Recruiting PHASE4

    Status: Not Yet Recruiting → Recruiting

  2. Dec 2022 — Jun 2023 [monthly]

    Not Yet Recruiting PHASE4

  3. Jun 2022 — Dec 2022 [monthly]

    Not Yet Recruiting PHASE4

  4. Apr 2022 — Jun 2022 [monthly]

    Not Yet Recruiting PHASE4

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • The University of Hong Kong
Data source: The University of Hong Kong

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Hong Kong, Hong Kong